Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Inovio INO, +2.75% gained 22.8% in premarket trading on Wednesday after the company said its COVID-19 vaccine candidate demonstrated neutralizing antibodies in animals.

Inovio's stock gains on early data testing its COVID-19 vaccine in animals

You can call INO a coronavirus stock, but it's really much more than that.
The post Add Inovio Stock to Your High-Growth Biotech Holdings appeared first on InvestorPlace.

Add Inovio Stock to Your High-Growth Biotech Holdings

If Inovio Pharmaceuticals' human trial results are as solid as the world hopes, INO stock could quickly race to $20.
The post Inovio Shows Plenty of Promise Outside of the Coronavirus appeared first on InvestorPlace.

Inovio Shows Plenty of Promise Outside of the Coronavirus

Investor Sentiment For Inovio Driven By Progress Of Its COVID-19 Vaccine

Inovio is a step behind Moderna on the coronavirus vaccine timeline -- but study results will determine the true winner.

Is Inovio Gaining Ground in the Coronavirus Vaccine Race?

Moderna

The University of Oxford, which is partnering with large-cap pharma AstraZeneca plc (NYSE: AZN) to develop a vaccine for SARS-CoV-2, could lead the pack in advancing its vaccine candidate to the next stage.

Results From Oxford University's Human Trial Of Coronavirus Vaccine Could Arrive In June; Where Inovio, Moderna Stand

PLYMOUTH MEETING, Pa., May 14, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) today announced that 85 percent (44 out of 52) of patients newly diagnosed with the deadly brain cancer glioblastoma multiforme (GBM) who received the company's DNA medicine INO-5401, in combination with INO-9012 and...

INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment

The clinical results from Inovo's INO-4700 validate the upside potential in INO stock.
The post Inovio Stock Shows Plenty of Promise Ahead appeared first on InvestorPlace.

Inovio Stock Shows Plenty of Promise Ahead

The company is racing through the early stage of the development of its potential vaccine for COVID-19.

Why Inovio Pharmaceuticals Jumped 8.7% Today

Despite Inovio Pharmaceuticals Inc's (NASDAQ: INO) first-quarter miss Monday, the sell-side remains largely upbeat on company, which is developing a coronavirus vaccine candidate.

Inovio Analysts Tackle Coronavirus Vaccine Timeline, Funding, Pipeline After Q1 Report

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET

Inovio Pharmaceuticals, Inc. (INO) CEO J. Joseph Kim on Q1 2020 Results - Earnings Call Transcript

Inovio Pharmaceuticals Inc (NASDAQ: INO), one of the frontrunners among companies developing vaccines for the coronavirus, reported Monday after the close with first-quarter results that trailed expectations.

Inovio Q1 Results Miss Estimates, Coronavirus Vaccine Program On Track

Inovio Pharmaceuticals Inc (NASDAQ: INO) along with Moderna Inc (NASDAQ: MRNA) are front-runners among the companies developing vaccines for the SARS-CoV-2, the virus that causes COVID-19.

Inovio To Report Q1 Results As It Develops Coronavirus Vaccine: What To Expect

BioNTech SE

Emergent BioSolutions

GlaxoSmithKline

Johnson & Johnson

Novavax

Pfizer

Sanofi

Sinovac Biotech

Is There A Safer Way to Invest in a Coronavirus Vaccine?

Can a company that failed multiple times to deliver vaccines for previous epidemics finally succeed?

Does Inovio Pharmaceuticals Have a Successful Track Record of Developing Vaccines?

With White House health advisor Dr. Anthony Fauci’s endorsement of Gilead Sciences’ remdesivir, INO stock now seems irrelevant.

Inovio Pharmaceuticals Is Hurting From Remdesivir but It’s Still Standing

Inovio shares climbed as the company’s coronavirus vaccine entered clinical trials.

Why Inovio Shares Rose 61.7% in April

Aflac

Clorox

Dynatrace Inc

Gilead Sciences

Home Depot

Honeywell

Sturm, Ruger & Company

Teladoc

Zoom Video

With pandemic fears shuttering many economies, most investments have cratered. However, a small group of coronavirus stocks may offer significant upside potential.

10 Stocks to Buy as They Ride a Coronavirus Tailwind

American Airlines

Aurora Cannabis

Boeing

Carnival

Disney

Ford Motor Company

General Electric

Microsoft

Tesla

Young investors aggressively bought the stock market dip in March, and here are the 10 stocks they bought the most.

10 Hot Stocks Young Investors Bought as Coronavirus Hit

Inovio: A Strong Sell

Inovio stock doesn't have the fundamentals to back up its bullish-leaning technicals. Here's what do with INO stock as a result.

The Fundamentals Say the Time to Buy INO Stock Has Passed

After shareholder pushback against its initial vaccine candidate announcement in February, Inovio badly needs its fraught clinical trial to succeed.

Inovio Is in a Race to Develop a COVID-19 Vaccine, but Can It Possibly Win?

The biotech is moving quickly, but has a lot of potential competition.

Inovio Ramps Up Production of Its Coronavirus Vaccine Candidate

Although Inovio Pharmaceuticals Inc (NASDAQ: INO) reported positive interim results from Phase 1 and 2a of its MERS vaccine, the valuation of the stock already reflects this, especially given the increase in share count since the end of 2019, according to Roth Capital Partners.

Roth Downgrades Inovio On Valuation Despite Positive MERS Vaccine Data

Investors should avoid INO stock and buy MRNA stock instead on weakness because Moderna's credentials are much more impressive at this point. 
The post Why Investors Should Avoid Inovio Pharmaceuticals appeared first on InvestorPlace.

Why Investors Should Avoid Inovio Pharmaceuticals

News for Inovio Pharmaceuticals Stock (INO)